ATE228361T1 - Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen - Google Patents

Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Info

Publication number
ATE228361T1
ATE228361T1 AT97928368T AT97928368T ATE228361T1 AT E228361 T1 ATE228361 T1 AT E228361T1 AT 97928368 T AT97928368 T AT 97928368T AT 97928368 T AT97928368 T AT 97928368T AT E228361 T1 ATE228361 T1 AT E228361T1
Authority
AT
Austria
Prior art keywords
reducing
compounds
cardiotoxicity
manganeous
antitumor drugs
Prior art date
Application number
AT97928368T
Other languages
English (en)
Inventor
Robertson Towart
Jan Olof Gustav Karlsson
Per Jynge
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE228361T1 publication Critical patent/ATE228361T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT97928368T 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen ATE228361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001721 WO1997049390A1 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Publications (1)

Publication Number Publication Date
ATE228361T1 true ATE228361T1 (de) 2002-12-15

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Country Status (14)

Country Link
US (2) US6147094A (de)
EP (2) EP0936915B1 (de)
JP (2) JP4359651B2 (de)
CN (2) CN1228694A (de)
AT (2) ATE225178T1 (de)
AU (2) AU720570B2 (de)
BR (1) BR9709942A (de)
CA (2) CA2259150A1 (de)
DE (2) DE69717447T2 (de)
GB (1) GB9613182D0 (de)
IL (1) IL127733A0 (de)
NO (2) NO985917L (de)
NZ (2) NZ333357A (de)
WO (2) WO1997049390A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527072A (ja) * 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR101312880B1 (ko) 1999-10-01 2013-09-30 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
ES2388064T3 (es) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Formulaciones liposomales de agentes de antraciclina y análogos de citidina
RU2433818C2 (ru) 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
CA2708113C (en) 2007-12-14 2017-08-22 Pledpharma Ab Compounds for use in the treatment of cancer
BR112012000262A2 (pt) * 2009-07-06 2016-02-16 Pledpharma Ab composição farmacêutica, e, método de tratamento de uma condição.
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
RU2765805C2 (ru) 2012-01-05 2022-02-03 Эгетис Терапьютикс Аб Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US20150313921A1 (en) 2012-11-02 2015-11-05 Pledpharma Ab Cancer Treatment Methods
AU2015277494A1 (en) 2014-06-16 2017-01-12 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verbesserung des therapeutischen index für ein chemotherapeutikum
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
EP3506942B1 (de) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1-bindende wirkstoffzusammensetzungen zur behandlung von krebs
US11427637B2 (en) 2016-09-06 2022-08-30 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
WO1997049390A1 (en) 1997-12-31
CN1228703A (zh) 1999-09-15
NO985916L (no) 1999-01-25
CN1228694A (zh) 1999-09-15
AU720621B2 (en) 2000-06-08
NO985917D0 (no) 1998-12-17
NZ333315A (en) 2000-07-28
GB9613182D0 (en) 1996-08-28
CA2258299A1 (en) 1997-12-31
ATE225178T1 (de) 2002-10-15
AU3268897A (en) 1998-01-14
NZ333357A (en) 2000-08-25
DE69717447T2 (de) 2003-09-11
JP4359651B2 (ja) 2009-11-04
DE69716104D1 (de) 2002-11-07
EP0936915A1 (de) 1999-08-25
US6258828B1 (en) 2001-07-10
BR9709942A (pt) 1999-08-10
AU720570B2 (en) 2000-06-08
EP0910360A1 (de) 1999-04-28
NO985916D0 (no) 1998-12-17
JP4162263B2 (ja) 2008-10-08
JP2000513351A (ja) 2000-10-10
CA2259150A1 (en) 1997-12-31
IL127733A0 (en) 1999-10-28
EP0936915B1 (de) 2002-10-02
DE69717447D1 (de) 2003-01-09
JP2000514044A (ja) 2000-10-24
EP0910360B1 (de) 2002-11-27
US6147094A (en) 2000-11-14
AU3268997A (en) 1998-01-14
DE69716104T2 (de) 2003-05-28
WO1997049409A1 (en) 1997-12-31
NO985917L (no) 1999-01-25

Similar Documents

Publication Publication Date Title
ATE228361T1 (de) Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
DE69703294T2 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
EP0911039A3 (de) Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner
MY135985A (en) Antitumor synergistic composition.
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
BR9912327A (pt) Inibidores da uroquinase
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
MX9601994A (es) Profarmacos de derivados de paclitaxel.
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
HK1032534A1 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
EA200100353A1 (ru) Применение производного антрациклина для лечения опухоли печени
DK0777498T3 (da) Konjugater fremstillet af metalkomplekser og oligonucleotider
WO2002038566A3 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
WO2001000189A3 (de) Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln
ES2195922T3 (es) Composicion sinergica que comprende derivados de daunorrubicina y compuestos antimetabolitos.
FI965166A (fi) Uusia kasvaimen- ja leukemianvastaisia aineita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties